Drug discovery

#Artificial intelligence (AI) #Computational chemistry #Digital workflow #Drug discovery #Machine learning #Webinar

Webinar: How is AI revolutionising drug discovery?

A new FREE TO ATTEND webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More

Webinar date:
Supported by Sapio Sciences
#News

#Cancer research #Drug discovery

Technical Note – Optimise your Macrophage Assays and Boost your Immunology Research

Download this technical note to learn: Streamlined Macrophage Workflow: Transform cryopreserved or PBMC-derived monocytes into M1 or M2 macrophages using a reproducible, high-throughput protocol. Comprehensive Validation: Confirm phenotype and function with live-cell imaging and phagocytosis assays for application-ready results. Accelerated Research: Enhance drug discovery, immunotoxicology, and screening workflows with both… Read More

#Technical Notes

#Drug discovery

Guide – Accelerate your imaging research with our updated protocols guide

This imaging protocol handbook will help you accelerate your research by helping you plan and execute your imaging experiments. The guide covers main procedural steps to achieve your best results. Plan and optimise imaging experiments with clear, step-by-step procedural guidance. Master core and advanced techniques—from cell proliferation and… Read More

#Guides

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Generative AI

From knowledge to creation: keeping up with AI 

Generative AI is now rapidly disrupting entire industries and new technology breakthroughs are emerging at pace. As new iterations push the boundaries of deep research and insight generation, the implications for life sciences are both profound and uncertain. Reflecting on the rapid progression of GenAI, and its potential to propel… Read More

#Exclusive Content

#Artificial intelligence (AI) #Automation / robotics #Drug discovery #Hit identification #Hit to lead

Unlocking hit-to-lead efficiency through AI and automation

Veronica DeFelice, Director of Biologic Products at Sapio Sciences, looks at how the hit-to-lead process in drug discovery is being impacted by AI and automation. Complexity at the core of hit-to-lead Hit-to-lead (H2L) screening is a critical phase in drug discovery, where researchers narrow down large libraries of compounds, small molecules,… Read More

#Exclusive Content

#App note #Artificial intelligence (AI) #Drug discovery #Imaging

App Note: Your AI-enhanced solution for viral infectivity analysis

Discover how the Agilent BioTek Cytation cell imaging multimode reader and ViQi’s AVIA provide a powerful, integrated solution for viral infectivity analysis. Download the Application Note to explore how this innovative approach offers key advantages over traditional assays, including: High-throughput, cost-effective analysis: AVIA minimises reagent use, incubation time, and replicate… Read More

#News

Scientist working with multi well plate for cell culture in the lab
#Antibody drug conjugate (ADC) #Drug discovery #GPCRs #Reagents #Revvity

Revvity launches new reagents for GPCR research

Revvity has launched pHSense reagents, designed to advance internalisation studies in drug discovery.   pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs).  Developed for use with standard plate readers, pHSense reagents combine a… Read More

#News

#Drug discovery #Goldilocks molecules #Synthetic biology #Synthetic libraries

Goldilocks molecules: Unlocking the next frontier in drug discovery

Christian Schafmeister, Founder and President of Thirdlaw Molecular, explores the promise of Goldilocks-sized molecules, the chemistry and design principles behind them and the technologies enabling rapid development of high-affinity binders against previously undruggable targets. For decades, the pharmaceutical industry has thrived on a foundational paradigm: small molecules for intracellular targets… Read More

#Exclusive Content

#Career #Drug discovery #Interview #Meet the Researcher

Meet the researcher: Graham Hatfull, University of Pittsburgh

Diana Turner caught up with Graham Hatfull, Eberly Family Professor of Biotechnology at the University of Pittsburgh, following his election to the Fellowship of the Royal Society. DT: Can you tell us what you do and what you’re working on at the moment?  GH: My lab studies bacteriophages (phages), which are viruses… Read More

#Exclusive Content #Opinion

#Artificial intelligence (AI) #Computational chemistry #Digital workflow #Drug discovery #Machine learning #Webinar

Webinar: Transforming drug discovery with AI and digital labs

A new free to attend webinar ‘Transforming drug discovery with AI and digital labs‘, hosted by DDW and supported by Sapio Sciences, is now open for registrations. On 15 September at 4pm BST, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational… Read More

Webinar date:
Supported by Sapio Sciences
#News

#Artificial intelligence (AI) #Computational chemistry #Digital workflow #Drug discovery #Machine learning

Transforming drug discovery with AI and digital labs

In this FREE TO ATTEND webinar, hosted by DDW and supported by Sapio Sciences, join Dr Rajesh Kumar, Senior Director of Structural Biology at Schrödinger, as he explores how advanced computational methods, AI, and machine learning are revolutionising drug discovery. Dr Kumar highlights how Schrödinger’s physics-based simulations and Free Energy… Read More

Webinar date:
Supported by Sapio Sciences
#Webinars

Human brain
#Drug discovery #Multiple sclerosis #Neurodegenerative disorders #Neuroscience

Does EBV trigger multiple sclerosis and drive its progression?

Evelyn Peelen, Head of Research, Andreas Muehler, Chief Medical Officer, and Hella Kohlhof, Chief Scientific Officer at Immunic Therapeutics discuss the unmet need for MS treatments that combine neuroprotective, anti-inflammatory, and antiviral properties. For a long time, multiple sclerosis (MS) has been viewed as a disease driven solely by peripheral… Read More

#Exclusive Content

#AI #Dermatology #Drug discovery

Almirall and Absci extend partnership tackling dermatological conditions  

Biopharmaceutical companies Almirall and Absci have announced an expansion of their ongoing partnership targeting dermatological indications.   The expansion of the collaboration follows the successful delivery of AI-designed, functional antibody leads against a difficult-to-drug target—the first target addressed within the initial collaboration between Almirall and Absci.  … Read More

#News

#Artificial intelligence (AI) #Collaboration #Drug discovery #Peptides

AI-powered platform could accelerate peptide drug discovery

CRDMO BioDuro and Atombeat have announced a strategic collaboration on an AI powered platform for accelerated peptide drug discovery.  The collaboration brings together Atombeat’s in silico modeling, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology and DMPK.  The combined platform aims… Read More

#News

#AI / data analytics / healthtech / informatics #Chromatography #Drug discovery

How data standards are revolutionising chromatography data workflows

Burkhard Schaefer, Managing Director of Splashlake, explores how chromatography is being impacted by emerging data standards. In drug discovery, every inefficiency in experimental workflows costs time, money, and the chance to bring life-saving treatments to patients. Chromatography has long been hampered by data silos, proprietary formats, and disconnected instrumentation. But… Read More

#Exclusive Content